Novel Treatment to Enhance Smoking Cessation Before Cancer Surgery
- Conditions
- Smoking Cessation
- Registration Number
- NCT02402023
- Lead Sponsor
- Yale University
- Brief Summary
The purpose of this clinical trial is to determine the feasibility and efficacy of an intervention designed to increase rates of tobacco abstinence for cancer patients before their cancer surgery.
- Detailed Description
The investigators are proposing a developmental interdisciplinary pilot study to determine the feasibility and efficacy of an intervention designed to increase rates of tobacco abstinence for cancer patients before their cancer surgery. This study (a follow up to smaller pilot studies) will serve as a means to further develop a treatment protocol and to generate an accurate effect size for a full scale trial. The present study will constitute a development clinical trial with a primary aim of developing an effect size for smoking cessation at the time of surgery (7-day point prevalence abstinence), and a secondary aim of creating an effect size for long-term abstinence at 3 months post-surgery.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
- age 18 or older
- smoking ≥ 1 cigarettes per day
- CO > 6 ppm
- diagnosed with or suspicion of any type of operable thoracic, head and neck, breast, or gynecologic cancer
- agreement on a 2-5-week pre-surgical tobacco intervention by both patient and surgeon, and 6) residence within reasonable driving distance to New Haven.
- unstable psychiatric conditions such as suicidal ideation, acute psychosis, severe alcohol dependence, or dementia
- unstable medical conditions that have not been well controlled (e.g., acute infection requiring hospitalization) for the past 30 days
- pregnant or breastfeeding women
- those with limited decision making capacity.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Pre Surgery Smoking Abstinence Day of Surgery Participants will be classified as succeeded or failed in cessation based on a definition of 1 week of abstinence from cigarettes leading up to the day of their surgery based on self-report and confirmed with biochemical verification (CO≤6ppm). For participants who are classified as abstinent, a chi-square will be computed comparing whether treatment with CM is superior to SC in producing a higher probability of abstinence. These data will be used to compute an effect size, Cohen's w, for smoking cessation.
- Secondary Outcome Measures
Name Time Method Post Surgery Smoking Abstinence 3 months Participants will be classified 3 months post surgical procedure as succeeded or failed in cessation based on self-report and confirmed with biochemical verification (CO≤6ppm) in the 7 days prior to the 3-month follow-up. For participants who are classified as abstinent, a chi-square will be computed comparing whether treatment with CM is superior to SC in producing a higher probability of abstinence.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (2)
Yale Cancer Center
🇺🇸New Haven, Connecticut, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Yale Cancer Center🇺🇸New Haven, Connecticut, United States